This project will unleash the potential of peptide drugs by overcoming their final barrier to widespread use, their synthesis. Plants naturally produce ultra-stable cyclic peptides. We will co-opt their machinery to produce in seeds, two drug leads that have potential as treatments for prostate cancer and chronic neuropathic pain. As an �organic� drug source, seeds have the potential to improve patient compliance and low-tech production systems will allow technology transfer to third-world natio ....This project will unleash the potential of peptide drugs by overcoming their final barrier to widespread use, their synthesis. Plants naturally produce ultra-stable cyclic peptides. We will co-opt their machinery to produce in seeds, two drug leads that have potential as treatments for prostate cancer and chronic neuropathic pain. As an �organic� drug source, seeds have the potential to improve patient compliance and low-tech production systems will allow technology transfer to third-world nations.Read moreRead less
Self Adjuvanting CTL-Based Influenza Vaccines For Human Use
Funder
National Health and Medical Research Council
Funding Amount
$214,842.00
Summary
This project will generate novel vaccines that elicit cell-mediated immunity against influenza infection. The vaccines are totally synthetic and therefore not constrained by the limitations in manufacturing which currently confront egg-grown vaccines. These vaccines induce very strong immune responses because they target dendritic cells which are pivotal for induction of all immune responses. This targeting capability is due to a simple lipid molecule incorporated into the vaccine which is recog ....This project will generate novel vaccines that elicit cell-mediated immunity against influenza infection. The vaccines are totally synthetic and therefore not constrained by the limitations in manufacturing which currently confront egg-grown vaccines. These vaccines induce very strong immune responses because they target dendritic cells which are pivotal for induction of all immune responses. This targeting capability is due to a simple lipid molecule incorporated into the vaccine which is recognised by specific receptors on the surface of dendritic cells and also causes their maturation, a step which is essential for recognition by the immune system of potential pathogens. The technology to design and assemble these new vaccines is already.Read moreRead less